1
|
Cartau T, Eldin C, Le Turnier P, Eskenazi A, Walter G, Coignard C, Schrooten W, Caumes E, Djossou F, Epelboin L. Is there Lyme borreliosis in French Guiana? Descriptive study among patients referred for a suspected Lyme borreliosis in an Amazonian hospital between 2010 and 2022. Ticks Tick Borne Dis 2024; 15:102255. [PMID: 37734165 DOI: 10.1016/j.ttbdis.2023.102255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 08/25/2023] [Accepted: 09/01/2023] [Indexed: 09/23/2023]
Abstract
Lyme borreliosis (LB) existence in South America is debated, especially in the Amazon region. The infection with Lyme borreliae has never been reported in French Guiana where Borrelia burgdorferi sensu lato is not found in ticks. We describe the final diagnosis and presumed place of acquisition in patients consulting for suspicion of LB. We retrospectively collected data from all consecutive patients consulting for a suspicion of LB between 2010 and 2021 at Cayenne Hospital, French Guiana. Patients were classified by an adjudication committee as confirmed LB if they met the criteria of the French consensus, as possible LB if they had compatible symptoms and a good outcome after appropriate treatment, or excluded when a differential diagnosis was found. The place of acquisition was discussed in case of possible or confirmed case. Twenty-six patients were included. Rheumatologic symptoms were the most reported (88 %) followed by neurological symptoms (61 %). Twenty-four (92 %) of these patients were born out of French Guiana. Diagnosis of LB was considered as confirmed in 2 patients (8 %), for whom the place of acquisition was likely mainland France, and as possible in 3 patients (11 %) with early localized LB presumably acquired in French Guiana. Functional somatic disorders were diagnosed in 13 (50 %) patients whereas 9 (35 %) were found with another disease. This study did not confirm the acquisition of LB in French Guiana. However, three possible autochthonous cases encourage clinicians working in the Amazon area to stay aware of LB.
Collapse
Affiliation(s)
- Tom Cartau
- Department of Infectious Diseases, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France.
| | - Carole Eldin
- Unité des virus émergents, Aix Marseille University, AP-HM, Chemin des Bourrely, 13015, Marseille, France
| | - Paul Le Turnier
- Department of Infectious Diseases, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France; CIC Inserm 1424, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France
| | - Anaïs Eskenazi
- Department of Internal Medicine, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France
| | - Gaëlle Walter
- Department of Infectious Diseases, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France
| | - Catherine Coignard
- Medical Biologist, Eurofins Biomnis, 78 avenue de Verdun, 94208, Ivry-sur-Seine, France
| | - Ward Schrooten
- Department of Medical Information, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France; Faculty of Medicine and Life Sciences, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium
| | - Eric Caumes
- Department of Infectious Diseases, Hospital Hotel Dieu, 1 place du Parvis Notre Dame, 75004, Paris, France
| | - Félix Djossou
- Department of Infectious Diseases, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France
| | - Loïc Epelboin
- Department of Infectious Diseases, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France; CIC Inserm 1424, Hospital of Cayenne, rue des Flamboyants, 97306, Cayenne, France
| |
Collapse
|
2
|
Aissaoui H, Eskenazi A, Suteau V, Adenis A, Drak Alsibai K. Reporte de caso: Papel potencial de los corticosteroides en el tratamiento de la neumonía post-COVID-19. Kompass Neumol 2022. [PMCID: PMC9059001 DOI: 10.1159/000521869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Houari Aissaoui
- Departamento de Medicina, Unidad de Pulmonología, Centro Hospitalario Andrée Rosemon, Cayenne, Guayana
- *Houari Aissaoui,
| | - Anaïs Eskenazi
- Departamento de Medicina, Centro Hospitalario Andrée Rosemon, Cayenne, Guayana
| | - Valentin Suteau
- Departamento de Patología, Centro Hospitalario Andrée Rosemon, Cayenne, Guayana
| | - Antoine Adenis
- Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Centro Hospitalario Andrée Rosemon, Cayenne, Guayana
| | - Kinan Drak Alsibai
- Departamento de Patología, Centro Hospitalario Andrée Rosemon, Cayenne, Guayana
- Centro de Recursos Biológicos (CRB Amazonie), Centro Hospitalario Andrée Rosemon, Cayenne, Guayana
| |
Collapse
|
3
|
Aissaoui H, Eskenazi A, Suteau V, Adenis A, Drak Alsibai K. Case Report: Potential Role of Corticosteroids in the Management of Post-COVID-19 Pneumonia. Front Med (Lausanne) 2021; 8:686806. [PMID: 34568360 PMCID: PMC8458727 DOI: 10.3389/fmed.2021.686806] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Accepted: 07/26/2021] [Indexed: 12/29/2022] Open
Abstract
Certain patients who recover from severe pneumonia due to coronavirus disease 2019 (COVID-19) remain symptomatic in the post-infectious period, either clinically, radiologically, or respiratory. The post-COVID-19 period is characterized by clinical symptoms of varying duration from one subject to another and does not seem to depend on the severity of initial pneumonia. The persisting inflammatory and/or immune reactions in the post-COVID-19 period may play a role in the development of pulmonary lesions. Here, we report the case of a 61-year-old man with severe COVID-19 pneumonia, complicated by acute respiratory distress syndrome and pulmonary embolism, which required the patient's admission to the intensive care unit and high-flow oxygen therapy. The patient was hospitalized for 23 days for the management of his severe COVID-19 pneumonia. Afterwards, he was discharged home following a negative SARS-CoV-2 PCR test. The post-COVID-19 period was characterized by a complex respiratory symptomatology associating cough, resting dyspnea, and exertional dyspnea requiring oxygen therapy for several weeks. Surprisingly, the follow-up chest CT scan performed 4 weeks after discharge revealed bilateral interstitial lung lesions. After ruling out pulmonary superinfection, the patient was treated with oral corticosteroid for 3 months at a digressive dose. In our case, the use of corticosteroid therapy in the post-COVID19 phase had improved the outcome of the lung disease. These benefits are characterized by a rapid symptomatic improvement, accelerated repair of pulmonary images, rapid oxygen withdrawal, and rapid return to daily activities.
Collapse
Affiliation(s)
- Houari Aissaoui
- Department of Medicine, Pulmonology Unit, Cayenne Hospital Center Andrée Rosemon, Cayenne, French Guiana
| | - Anaïs Eskenazi
- Department of Medicine, Cayenne Hospital Center Andrée Rosemon, Cayenne, French Guiana
| | - Valentin Suteau
- Department of Pathology, Cayenne Hospital Center Andrée Rosemon, Cayenne, French Guiana
| | - Antoine Adenis
- Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Cayenne Hospital Center Andrée Rosemon, Cayenne, French Guiana
| | - Kinan Drak Alsibai
- Department of Pathology, Cayenne Hospital Center Andrée Rosemon, Cayenne, French Guiana.,Center of Biological Resources (CRB Amazonie), Cayenne Hospital Center Andrée Rosemon, Cayenne, French Guiana
| |
Collapse
|
4
|
Sculier J, Botta I, Bucalau A, Compagnie M, Eskenazi A, Fischler R, Gorham J, Mans L, Rozen L, Speybrouck S, Wang X, Meert A, Berghmans T. Medical anticancer treatment of lung cancer associated with comorbidities: A review. Lung Cancer 2015; 87:241-8. [DOI: 10.1016/j.lungcan.2015.01.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Accepted: 01/09/2015] [Indexed: 12/26/2022]
|
5
|
Batova A, Yu AL, Strother D, Angelini P, Eskenazi A. Promising results of a pilot trial of a GD2 directed anti-idiotypic antibody as a vaccine for high risk neuroblastoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8511] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Batova
- UCSD, San Diego, CA; University of Calgary, Calgary, AB, Canada; University of Turin, Turin, Italy; University of Maryland, Baltimore, MD
| | - A. L. Yu
- UCSD, San Diego, CA; University of Calgary, Calgary, AB, Canada; University of Turin, Turin, Italy; University of Maryland, Baltimore, MD
| | - D. Strother
- UCSD, San Diego, CA; University of Calgary, Calgary, AB, Canada; University of Turin, Turin, Italy; University of Maryland, Baltimore, MD
| | - P. Angelini
- UCSD, San Diego, CA; University of Calgary, Calgary, AB, Canada; University of Turin, Turin, Italy; University of Maryland, Baltimore, MD
| | - A. Eskenazi
- UCSD, San Diego, CA; University of Calgary, Calgary, AB, Canada; University of Turin, Turin, Italy; University of Maryland, Baltimore, MD
| |
Collapse
|
6
|
Toretsky JA, Steinberg SM, Thakar M, Counts D, Pironis B, Parente C, Eskenazi A, Helman L, Wexler LH. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001; 92:2941-7. [PMID: 11753970 DOI: 10.1002/1097-0142(20011201)92:11<2941::aid-cncr10072>3.0.co;2-c] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND Ewing sarcoma family of tumors (ESFTs) are the second most common bone tumor, that most often affects persons ages 3-40 years. The ESFTs rely on signaling through the insulin-like growth factor-1 receptor (IGF-1R) for growth and transformation. The current studies were performed to determine the levels of IGF-1 and IGF binding protein-3 (IGFBP-3) in patients with ESFT. The authors then performed an exploratory analysis to evaluate whether IGF parameters could differentiate event free or overall survival in ESFT patients. METHODS The authors measured serum levels of IGF-1 and IGFBP-3 by using a radioimmunoassay from 111 patients with ESFT with a median follow-up of 13 years from diagnosis. RESULTS The IGF-1 levels were lower among patients with metastatic disease to the bones or the bone marrow compared with patients without metastasis to these sites (p2 = 0.021 and 0.0038, respectively). IGFBP-3 is known to sequester IGF-1; the ratios of IGFBP-3 to IGF-1 were evaluated. Patients with metastatic disease to any site had higher IGFBP-3 to IGF-1 ratios than patients with localized disease (p2 = 0.0067). There was a trend toward increased survival in patients with localized disease who had high IGFBP-3 to IGF-1 levels. Metastatic patients showed a similar trend. CONCLUSIONS Levels of IGF-1 and IGFBP-3 in ESFT patients can identify patients with the most widespread disease. The IGFBP-3 to IGF-1 ratio in patients with either localized or metastatic disease identified patients with a trend toward increased survival. Further prospective evaluation with higher patient numbers might show a prognostic role for the IGFBP-3 to IGF-1 ratio in patients with ESFT.
Collapse
Affiliation(s)
- J A Toretsky
- Department of Pediatrics, University of Maryland, Baltimore, Maryland, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
O'Brien KL, Swift AJ, Winkelstein JA, Santosham M, Stover B, Luddy R, Gootenberg JE, Nold JT, Eskenazi A, Snader SJ, Lederman HM. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics 2000; 106:965-72. [PMID: 11061761 DOI: 10.1542/peds.106.5.965] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
OBJECTIVES To determine the immunogenicity and safety of heptavalent pneumococcal polysaccharide vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to CRM(197) (7-valent conjugate pneumococcal vaccine [7VPnC]) among infants with sickle cell disease (SCD) and a comparison group of infants without SCD (non-SCD). DESIGN Two cohorts of infants were enrolled and received open-label doses of 7VPnC vaccine; infants enrolled before 2 months of age received 7VPnC vaccine at 2, 4, and 6 months of age followed by 23-valent pneumococcal polysaccharide vaccine (PS-23) at 24 months of age for those infants with SCD (schedule A), and infants enrolled between 2 and 12 months of age received 7VPnC at 12 months of age followed by PS-23 at 24 months of age for infants with SCD (schedule B). Safety data were collected for 3 days after each dose of vaccine. Antibody concentrations were measured to each of the 7VPnC serotypes by enzyme-linked immunosorbent assay before each vaccine dose and 1 month after the last 7VPnC dose and the PS-23 vaccine dose. RESULTS Forty-five infants (34 SCD and 11 non-SCD) were vaccinated according to schedule A and 16 infants (13 SCD and 3 non-SCD) according to schedule B. The 7VPnC vaccine was highly immunogenic for all serotypes among infants with and without SCD who received 3 doses of vaccine according to schedule A: depending on serotype, 89% to 100% achieved antibody concentrations above.15 microg/mL and 56% to 100% achieved antibody concentrations above 1.0 microg/mL. Among infants immunized according to schedule B, a single dose of 7VPnC vaccine resulted in antibody concentrations above.15 microg/mL in 53% to 92% by serotype and above 1.0 microg/mL in 31% to 71% by serotype. A single dose of PS-23 resulted in dramatic increases in the antibody concentrations to all serotypes regardless of 1- or 3-dose priming. There was no difference in the reactogenicity of the 7VPnC vaccine between those with and without SCD. There were no serious reactions to the 7VPnC or PS-23 vaccines, even among those with high antibody concentrations before immunization. CONCLUSIONS Infants with SCD respond to 7VPnC vaccine with antibody concentrations that are at least as high as infants without SCD. Infants immunized with 7VPnC vaccine at 2, 4, and 6 months of age developed antibody concentrations in the same range as those achieved among infants without SCD enrolled in a large trial that demonstrated vaccine efficacy against invasive disease. Significant rises were seen in antibody concentrations to all 7VPnC serotypes after the PS-23 booster in children receiving schedule A or B.
Collapse
Affiliation(s)
- K L O'Brien
- Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland, 21205, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Wirth F, Perry R, Eskenazi A, Schwalbe R, Kao G. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. J Am Acad Dermatol 1997; 36:336-41. [PMID: 9039214 DOI: 10.1016/s0190-9622(97)80412-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Primary cutaneous mucormycosis is a rare opportunistic fungal infection that is usually limited to the skin. We describe a primary cutaneous Rhizopus infection occurring at a site occluded by a sterile adhesive dressing in which the disease was viscerally disseminated at the time fo diagnosis. Mucormycosis should be considered in all ecthyma-like lesions in immunocompromised patients. It may be rapidly diagnosed by examination of hematoxylin-eosin and PAS-stained sections of the eschar base and a culture of a leading edge tissue aspirate. We review 21 cases of primary cutaneous mucormycosis in children and compare them with the present case.
Collapse
Affiliation(s)
- F Wirth
- Department of Dermatology, University of Maryland School of Medicine, Baltimore, USA
| | | | | | | | | |
Collapse
|
9
|
Pallant A, Eskenazi A, Mattei MG, Fournier RE, Carlsson SR, Fukuda M, Frelinger JG. Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16. Proc Natl Acad Sci U S A 1989; 86:1328-32. [PMID: 2521952 PMCID: PMC286683 DOI: 10.1073/pnas.86.4.1328] [Citation(s) in RCA: 112] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
We describe the isolation and characterization of cDNA clones encoding human leukosialin, a major sialoglycoprotein of human leukocytes. Leukosialin is very closely related or identical to the sialophorin molecule, which is involved in T-cell proliferation and whose expression is altered in Wiskott-Aldrich syndrome (WAS), an X chromosome-linked immunodeficiency disease. Using a rabbit anti-serum to leukosialin, a cDNA clone was isolated from a lambda gt11 cDNA library constructed from human peripheral blood cells. This lambda gt11 clone was used to isolate longer cDNA clones that correspond to the entire coding sequence of leukosialin. DNA sequence analysis reveals three domains in the predicted mature protein. The extracellular domain is enriched for Ser, Thr, and Pro and contains four contiguous 18-amino acid repeats. The transmembrane and intracellular domains of the human leukosialin molecule are highly homologous to the rat W3/13 molecule. RNA gel blot analysis reveals two polyadenylylated species of 2.3 and 8 kilobases. Southern blot analysis suggests that human leukosialin is a single-copy gene. Analysis of monochromosomal cell hybrids indicates that the leukosialin gene is not X chromosome linked and in situ hybridization shows leukosialin is located on chromosome 16. These findings demonstrate that the primary mutation in WAS is not a defect in the structural gene for leukosialin.
Collapse
Affiliation(s)
- A Pallant
- Cancer Center Immunology Unit, University of Rochester Medical Center, NY 14642
| | | | | | | | | | | | | |
Collapse
|
10
|
Lubetzki J, Grupper C, Malbec D, Warnet A, Guillausseau PJ, Luyckx A, Hautefeuille P, Galian A, Scotto J, Rault P, Eskenazi A, Mathieu M. [Clinical, biological, histological, ultrastructural and therapeutic studies in one case (author's transl)]. Nouv Presse Med 1980; 9:1565-9. [PMID: 6258130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The diagnosis of glucagonoma was made in a 51 year-old woman who suffered from a polymorphous dermatitis and an insulin-dependent diabetes mellitus. Denutrition was present and there was a previous history of thrombo-embolism. Immunoreactive plasma glucagon was constantly higher than 1 000 pg/ml (N less than 175). Plasma aminoacids were low. After angiographic confirmation, the tumour and part of its hepatic metastases were resected. The dermatitis disappeared soon after. Its recurrence required chemotherapy (successively mithramycin, streptozotocin, DTIC) and good clinical results were obtained. On histological examination, the cutaneous lesions consisted of an epidermal edema, and a bullous intra-epidermic detachment. The pancreatic tumour was of the trabecular type with a very important sclerosis. On electron microscopy, the tumoral cells, some with a syncitial aspect, contained granules of the D1 type. These granules are different from the typical glucagon granules. The clinical and biological features in this case are compared with those of the 41 cases of glucagonoma previously published.
Collapse
|
11
|
Beltzer-Garelli E, Cesarini JP, Cywiner-Golenzer C, Eskenazi A, Grupper C. [Skin lesions revealing a glucagonoma (author's transl)]. Sem Hop 1980; 56:579-82. [PMID: 6245465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
About a case of necrolytic migratory erythema erythema revealing a malignant pancreatic glucagonoma, the authors compare the results of their study with the 25 cases published in the world.
Collapse
|